Concepedia

Publication | Open Access

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

DOIFull Paper Access

115

Citations

36

References

2015

Year

Ben Y. Durkee, Yushen Qian, Erqi L. Pollom, Martin T. King, S.A. Dudley, J. Shaffer, Daniel T. Chang, Iris C. Gibbs, Jeremy D. Goldhaber‐Fiebert, Kathleen C. Horst
Journal of Clinical Oncology

Abstract

THP in patients with metastatic HER2-positive breast cancer is unlikely to be cost effective in the United States.

References

YearCitations

Page 1